Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ZYRTEC HIVES versus PHENERGAN VC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ZYRTEC HIVES versus PHENERGAN VC.
CHILDREN'S ZYRTEC HIVES vs PHENERGAN VC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective antagonist of peripheral histamine H1 receptors, inhibiting histamine-mediated allergic reactions.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
5 mg or 10 mg orally once daily; maximum 10 mg/day.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
None Documented
None Documented
Terminal elimination half-life is approximately 8-11 hours in healthy adults, allowing twice-daily dosing.
9-16 hours; prolonged in hepatic impairment.
Cetirizine is primarily excreted renally (~60% unchanged), with ~10% fecal excretion.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination